Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Angiotensin-converting enzyme

4

6-phosphogluconate dehydrogenase, decarboxylating

1

Glucose-6-phosphate 1-dehydrogenase

1

Glutathione reductase

1

Sodium/potassium-transporting ATPase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1954

1

1991

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypertension

4

Chronic atrial fibrillation

1

Heart failure

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ciba-Geigy

4

Alexandria

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

FDA UNII

5

CHEBI

4

ChEMBL

4

DAILYMED

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

1

CARDIAC THERAPY

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ACE INHIBITORS, COMBINATIONS

1

ACE INHIBITORS, PLAIN

1

CARDIAC GLYCOSIDES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

ACE inhibitors and diuretics

1

ACE inhibitors, plain

1

Digitalis glycosides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

BENAZEPRILAT

JRM708L703

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and al...

so in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

Digoxin

73K4184T59

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First approved in 1954

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase

6-phosphogluconate dehydrogenase, decarboxylating

Glucose-6-phosphate 1-dehydrogenase

Glutathione reductase

Conditions:

Chronic atrial fibrillation

Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Digoxin inhibits...

the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX) in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

BENAZEPRIL, (±)-

PX47FSF9B3

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1991

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and al...

so in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

BENAZEPRIL

UDM7Q7QWP8

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and al...

so in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

BENAZEPRIL HYDROCHLORIDE

N1SN99T69T

Export Data
Search for Structure

Status:

US Approved Rx (2004)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and al...

so in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1